References
Referencesarepublicationsthatsupporttheproducts'biologicalactivity.
Ederetal(2009)Noveltherapeuticinhibitorsofthec-Metsignalingpathwayincancer.Clin.CancerRes.152207PMID:19318488
Timofeevskietal(2009)Enzymaticcharacterizationofc-Metreceptortyrosinekinaseoncogenicmutantsandkineticstudieswithaminopyridineandtriazolopyrazineinhibitors.Biochemistry485339PMID:19459657
Underineretal(2010)Discoveryofsmallmoleculec-Metinhibitors:evolutionandprofilesofclinicalcandidates.AnticancerAgentsMed.Chem.107PMID:20015007
Cuietal(2012)Discoveryofanovelclassofexquisitelyselectivemesenchymal-epithelialtransitionfactor(c-MET)proteinkinaseinhibitorsandidentificationoftheclinicalcandidate2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-J.Med.Chem.558091PMID:22924734
Keywords:PF04217903mesylate,supplier,pfizer,PF04217903,c-met,met,mesenchymal,epithelial,transition,factor,hgfr,receptors,tyrosine,kinase,rtk,inhibitors,inhibits,anticancer,selective,MET,Receptors,MET,Receptors,TocrisBioscience